AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28304227 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab
Number of subjects: 4300
Study 25442108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional cryosurgery
Number of subjects: 23
Study 25442108 — intervention group
Group type: COMPARATOR
Intervention: Contact cryosurgery
Number of subjects: 23
Study 25442108 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cryosurgical methods
Number of subjects: 23
Study 24787489 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA
Number of subjects: 17046
Study 24787489 — intervention group
Group type: COMPARATOR
Intervention: AGA
Number of subjects: 17046
Study 24787489 — intervention group
Group type: EXPERIMENTAL
Intervention: LGA
Number of subjects: 17046
Study 24787489 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA with catch-up growth
Number of subjects: 17046
Study 22928973 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance for low risk PCa
Number of subjects: 509
Study 22928973 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance for intermediate risk PCa
Number of subjects: 509
Study 22928973 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance for low and intermediate risk PCa
Number of subjects: 509
Study 18814001 — intervention group
Group type: EXPERIMENTAL
Intervention: FLS expert rating
Number of subjects: 26
Study 18814001 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion efficiency scores using ICSAD
Number of subjects: 26
Study 18814001 — intervention group
Group type: EXPERIMENTAL
Intervention: FLS expert scores
Number of subjects: 26
Study 17911777 — intervention group
Group type: EXPERIMENTAL
Intervention: Text classification augmented with a Hidden Markov Model
Number of subjects: 0
Study 15545060 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (800 microg of budesonide) for 12 weeks
Number of subjects: 45
Study 11244659 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal balloon ablation therapy
Number of subjects: 27
Study 11244659 — intervention group
Group type: COMPARATOR
Intervention: Gestagen therapy
Number of subjects: 27
Study 9850017 — intervention group
Group type: EXPERIMENTAL
Intervention: Short chemotherapy (6 months) with vincristine and dactinomycin (pulse-intensive)
Number of subjects: 905
Study 9850017 — intervention group
Group type: EXPERIMENTAL
Intervention: Long chemotherapy (9 additional months) with vincristine and dactinomycin (pulse-intensive)
Number of subjects: 905
Study 9850017 — intervention group
Group type: COMPARATOR
Intervention: Short PI treatment regimens
Number of subjects: 905
Study 8116277 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-informative cue presented at the same location as the target
Number of subjects: 0
Study 8116277 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-informative cue remained on view throughout the period of the SOA and terminated 300 msec after target onset
Number of subjects: 0
Study 8116277 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-informative cue with a duration of 130 msec
Number of subjects: 0
Study 8116277 — intervention group
Group type: EXPERIMENTAL
Intervention: Targets in cued locations
Number of subjects: 0
Study 30544793 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (received free vision care and eyeglasses)
Number of subjects: 2713
Study 30544793 — intervention group
Group type: COMPARATOR
Intervention: Control group (received glasses only at the end of the study)
Number of subjects: 2713
Study 30544793 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group membership
Number of subjects: 2713
Study 26758402 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 1% ointment
Number of subjects: 36
Study 26758402 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 36
Study 24987838 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative computed tomography (CT) based texture analysis (QTA)
Number of subjects: 48
Study 24987838 — intervention group
Group type: EXPERIMENTAL
Intervention: Kurtosis (QTA feature)
Number of subjects: 48
Study 22230174 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilingual program
Number of subjects: 188
Study 22230174 — intervention group
Group type: COMPARATOR
Intervention: English-only program
Number of subjects: 188
Study 19866403 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg of oral sildenafil every 6 hours
Number of subjects: 51
Study 19866403 — intervention group
Group type: COMPARATOR
Intervention: Placebo when the oxygenation index was >20
Number of subjects: 51
Study 18416077 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for one month at main points (Zhongwan (CV 12), Zusanli (ST 36), Taichong (LR 3), Shenmen (HT 7))
Number of subjects: 80
Study 18416077 — intervention group
Group type: COMPARATOR
Intervention: Domperidone orally administered for one month
Number of subjects: 80
Study 16938781 — intervention group
Group type: EXPERIMENTAL
Intervention: Second identical cochlear implant in the contralateral ear immediately
Number of subjects: 24
Study 16938781 — intervention group
Group type: COMPARATOR
Intervention: Control group (waited 12 months)
Number of subjects: 24
Study 16938781 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-case scenario (no worsening of tinnitus)
Number of subjects: 24
Study 14566831 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use (n = 68)
Number of subjects: 136
Study 14566831 — intervention group
Group type: COMPARATOR
Intervention: Noncondom use (n = 68)
Number of subjects: 136
Study 14566831 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-negative men (n not specified)
Number of subjects: 136
Study 14566831 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive men (n not specified)
Number of subjects: 136
Study 14566831 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent HPV status men (n not specified)
Number of subjects: 136
Study 10874273 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodromal unstable angina
Number of subjects: 196
Study 10874273 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, peak creatine kinase MB level, infarct location, combined variables
Number of subjects: 196
Study 10874273 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prodromal unstable angina)
Number of subjects: 196
Study 8626363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 206
Study 8626363 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 206
Study 1452964 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg dietary calcium per day
Number of subjects: 13
Study 1452964 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg dietary calcium per day
Number of subjects: 13
Study 1452964 — intervention group
Group type: COMPARATOR
Intervention: Baseline (low-calcium diet)
Number of subjects: 13
Study 6531653 — intervention group
Group type: EXPERIMENTAL
Intervention: alprenolol (n = 20)
Number of subjects: 37
Study 6531653 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 17)
Number of subjects: 37
Study 29782272 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 29782272 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 29782272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 29782272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0
Study 28095578 — intervention group
Group type: EXPERIMENTAL
Intervention: BTL Vanquish METM
Number of subjects: 36
Study 28095578 — intervention group
Group type: COMPARATOR
Intervention: VanquishTM
Number of subjects: 36
Study 26591358 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) group - WYHZTLR decoction (one dose per day)
Number of subjects: 36
Study 26591358 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine (WM) group - penicillamine tablet (0.125 g, bid) and Prednisone Acetate Tablet (PAT 20 mg, qd)
Number of subjects: 36
Study 26591358 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medicine (IM) group - penicillamine, PAT, and WYHZTLR decoction (same dosages as above)
Number of subjects: 36
Study 26591358 — intervention group
Group type: COMPARATOR
Intervention: Control group - untreated SSc patients' serum
Number of subjects: 36
Study 22917711 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (150mg increased to 250mg after 4 weeks)
Number of subjects: 15
Study 22917711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 20118171 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1302
Study 20118171 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1302
Study 19232061 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic interventions
Number of subjects: 0
Study 19232061 — intervention group
Group type: COMPARATOR
Intervention: Background therapy and/or early rescue
Number of subjects: 0
Study 19232061 — intervention group
Group type: EXPERIMENTAL
Intervention: Goals of remission and 'treating to targets'
Number of subjects: 0
Study 19232061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive safety evaluation during randomized controlled trials
Number of subjects: 0
Study 15689731 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized training of working memory (WM)
Number of subjects: 53
Study 15689731 — intervention group
Group type: COMPARATOR
Intervention: Comparison program (control)
Number of subjects: 53
Study 12810749 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported safety practices from a questionnaire
Number of subjects: 64
Study 12810749 — intervention group
Group type: COMPARATOR
Intervention: Home safety check (observation)
Number of subjects: 64
Study 10566728 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-303 (500 mg p.o. every 6 h for 96 h)
Number of subjects: 51
Study 10566728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8729191 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (endocrine therapy)
Number of subjects: 0
Study 1867617 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% plain bupivacaine (local injection)
Number of subjects: 80
Study 1867617 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% plain bupivacaine (topical application)
Number of subjects: 80
Study 1867617 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (control for local injection)
Number of subjects: 80
Study 1867617 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (control for topical application)
Number of subjects: 80
Study 6409958 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc load
Number of subjects: 72
Study 6409958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc load)
Number of subjects: 72
Study 6409958 — intervention group
Group type: EXPERIMENTAL
Intervention: MS patients
Number of subjects: 72
Study 6409958 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte membrane-bound CNP
Number of subjects: 72
Study 29432041 — intervention group
Group type: EXPERIMENTAL
Intervention: Community paramedic training in the CTI program, geriatrics, effective coaching, ED discharge processes, and community paramedicine.
Number of subjects: 8
Study 29432041 — intervention group
Group type: EXPERIMENTAL
Intervention: Community paramedic training in the CTI program.
Number of subjects: 8
Study 26876351 — intervention group
Group type: EXPERIMENTAL
Intervention: PRGF (n = 10)
Number of subjects: 30
Study 26876351 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF (n = 10)
Number of subjects: 30
Study 26876351 — intervention group
Group type: COMPARATOR
Intervention: Control (bone-substitute grafting, n = 10)
Number of subjects: 30
Study 26876351 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 24927851 — intervention group
Group type: EXPERIMENTAL
Intervention: Group follow-up (two group education 'booster' sessions post-DAFNE)
Number of subjects: 437
Study 22661076 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospectively ECG-triggered axial acquisition
Number of subjects: 150
Study 22661076 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospectively ECG-triggered high pitch spiral acquisition
Number of subjects: 150
Study 22661076 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard spiral acquisition
Number of subjects: 150
Study 19758763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention (CI) prior to injection with CRH
Number of subjects: 32
Study 19758763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19758763 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH stimulation
Number of subjects: 32
Study 18408924 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D TrueFISP
Number of subjects: 10
Study 18408924 — intervention group
Group type: COMPARATOR
Intervention: PD-FS-TSE
Number of subjects: 10
Study 18408924 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative T2 mapping
Number of subjects: 10
Study 16913455 — intervention group
Group type: EXPERIMENTAL
Intervention: School curriculum intervention on HIV/AIDS/STD prevention including emergency contraception (EC) information.
Number of subjects: 11117
Study 14504028 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP 8 mg s.l. tablet
Number of subjects: 5
Study 14504028 — intervention group
Group type: COMPARATOR
Intervention: METH 60 mg/day
Number of subjects: 5
Study 11106097 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg CIFN
Number of subjects: 187
Study 11106097 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 microg CIFN
Number of subjects: 187
Study 11106097 — intervention group
Group type: COMPARATOR
Intervention: 3 MU IFN-alpha-2a
Number of subjects: 187
Study 9347392 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine (200 mg per day)
Number of subjects: 284
Study 9347392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 8327705 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid contrast material
Number of subjects: 101
Study 8327705 — intervention group
Group type: COMPARATOR
Intervention: Air contrast material
Number of subjects: 101
Study 3027832 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of itraconazole daily
Number of subjects: 185
Study 3027832 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of itraconazole daily
Number of subjects: 185
Study 3027832 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg or 100 mg of itraconazole daily
Number of subjects: 185
Study 29484877 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic music therapy for 16 weeks in addition to usual physiotherapy
Number of subjects: 18
Study 29484877 — intervention group
Group type: COMPARATOR
Intervention: Usual therapeutic input without neurologic music therapy
Number of subjects: 18
Study 27706199 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Positive Outcome Ratio (SPOR) based on patient satisfaction
Number of subjects: 574
Study 27706199 — intervention group
Group type: EXPERIMENTAL
Intervention: High-scoring group of providers
Number of subjects: 574
Study 27706199 — intervention group
Group type: COMPARATOR
Intervention: Low-scoring group of providers
Number of subjects: 574
Study 24132773 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg soft-gel capsule of acetylsalicylic acid (ASA)
Number of subjects: 46
Study 24132773 — intervention group
Group type: COMPARATOR
Intervention: marketed powder for oral solution
Number of subjects: 46
Study 21850506 — intervention group
Group type: COMPARATOR
Intervention: TVT
Number of subjects: 177
Study 21850506 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 177
Study 21626815 — intervention group
Group type: EXPERIMENTAL
Intervention: Akatinol memantine (5-10 mg/day, increased to 20 mg/day over 90 days)
Number of subjects: 50
Study 21626815 — intervention group
Group type: COMPARATOR
Intervention: Neurorehabilitation without akatinol memantine (control group)
Number of subjects: 50
Study 17592907 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (2-15 mg/day with fluoxetine or paroxetine; 2-20 mg/day with all others)
Number of subjects: 362
Study 17592907 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 362
Study 17592907 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 362
Study 15912413 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (500 mug)
Number of subjects: 150
Study 15912413 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (2 mg)
Number of subjects: 150
Study 15912413 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg)
Number of subjects: 150
Study 15912413 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1 microg kg(‐1))
Number of subjects: 150
Study 15912413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (100 mg)
Number of subjects: 150
Study 15912413 — intervention group
Group type: COMPARATOR
Intervention: Saline (20 ml)
Number of subjects: 150
Study 11836043 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E2/0.5 mg NETA (low-dose HRT)
Number of subjects: 96
Study 11836043 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E2/1 mg NETA (high-dose HRT)
Number of subjects: 96
Study 10616118 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of Wakefulness Test (MWT)
Number of subjects: 522
Study 10616118 — intervention group
Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 522
Study 10616118 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Sleep Latency Test (MSLT)
Number of subjects: 522
Study 7488481 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 30
Study 7488481 — intervention group
Group type: COMPARATOR
Intervention: Oxygen-air mixture
Number of subjects: 30
Study 2023370 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% Bupranolol
Number of subjects: 0
Study 2023370 — intervention group
Group type: COMPARATOR
Intervention: 0.5% Timolol (preserved)
Number of subjects: 0
Study 2023370 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers in aqueous solution
Number of subjects: 0
Study 6758748 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid
Number of subjects: 60
Study 6758748 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida albicans
Number of subjects: 60
Study 6758748 — intervention group
Group type: COMPARATOR
Intervention: Tetanus toxoid and Candida albicans
Number of subjects: 60
Study 31990800 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of catheter immediately after surgery (group 1)
Number of subjects: 73
Study 31990800 — intervention group
Group type: COMPARATOR
Intervention: Standard overnight indwelling urethral catheterization (group 2)
Number of subjects: 73
Study 31990800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study 31804186 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-titration program
Number of subjects: 222
Study 31804186 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 222
Study 27435635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Intervention (CBI) for 5 weeks
Number of subjects: 60
Study 27435635 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 26446331 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg of 20% intravenous mannitol infusion over 10 minutes before induction of anesthesia (group M)
Number of subjects: 40
Study 26446331 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 40
Study 26446331 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg of 20% intravenous mannitol infusion (group M)
Number of subjects: 40
Study 24145068 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile bearing total knee arthroplasty
Number of subjects: 352
Study 24145068 — intervention group
Group type: COMPARATOR
Intervention: Fixed bearing total knee arthroplasty
Number of subjects: 352
Study 22455791 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol 0.5%‐dexamethasone 0.1% plus diclofenac 0.1%, 1 drop 3 times a day, plus diclofenac 0.1% for 3 days before surgery (n=38)
Number of subjects: 79
Study 22455791 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol 0.5%‐dexamethasone 0.1%, 1 drop 4 times a day (n=41)
Number of subjects: 79
Study 20230185 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free regimen (Tacrolimus, Mycophenolate mofetil, Basiliximab induction, steroids for 3 days)
Number of subjects: 100
Study 20230185 — intervention group
Group type: COMPARATOR
Intervention: Steroid maintenance regimen (Tacrolimus, Mycophenolate mofetil, Basiliximab induction, steroid maintenance)
Number of subjects: 100
Study 18056435 — intervention group
Group type: EXPERIMENTAL
Intervention: High cysteinylglycine levels in the vitamin E placebo group
Number of subjects: 812
Study 18056435 — intervention group
Group type: EXPERIMENTAL
Intervention: High cysteinylglycine levels in the high alcohol intake group (>or=9 g/day)
Number of subjects: 812
Study 18056435 — intervention group
Group type: EXPERIMENTAL
Intervention: High cysteinylglycine levels in the overweight and obese group
Number of subjects: 812
Study 16321271 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 59
Study 16321271 — intervention group
Group type: COMPARATOR
Intervention: Human soluble insulin
Number of subjects: 59
Study 12177729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-free lean body mass (BF-LBM)
Number of subjects: 118
Study 12177729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral content (BMC)
Number of subjects: 118
Study 12177729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass (FM)
Number of subjects: 118
Study 12177729 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex, age, height, and BF-LBM*Height
Number of subjects: 118
Study 12177729 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction equations based on sex, age, height, and BF-LBM*Height
Number of subjects: 118
Study 10025442 — intervention group
Group type: EXPERIMENTAL
Intervention: 85.8 g amino acid mixture lacking tryptophan
Number of subjects: 10
Study 10025442 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid mixture
Number of subjects: 10
Study 10025442 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (12 subjects)
Number of subjects: 10